Cargando…

Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US

PURPOSE: Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the use of BMAs (denosumab and intravenous bisphosphonates) among women in the US. PAT...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGrath, Leah J, Overman, Robert A, Reams, Diane, Cetin, Karynsa, Liede, Alexander, Narod, Steven A, Brookhart, M Alan, Hernandez, Rohini K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162990/ https://www.ncbi.nlm.nih.gov/pubmed/30288124 http://dx.doi.org/10.2147/CLEP.S175063

Ejemplares similares

Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States
por: McGrath, Leah J., et al.
Publicado: (2018)

Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States
por: McGrath, Leah J, et al.
Publicado: (2020)

Lipid Testing Trends in the US Before and After the Release of the 2013 Cholesterol Treatment Guidelines
por: Levintow, Sara N, et al.
Publicado: (2020)

Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
por: Cetin, Karynsa, et al.
Publicado: (2015)

Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States
por: Hernandez, Rohini K., et al.
Publicado: (2018)

Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States
por: Hernandez, Rohini K, et al.
Publicado: (2015)

SUN-389 Trends in Osteoporosis Treatment Uptake and Persistence Among Postmenopausal Women in the U.S., 2010–2015
por: Kim, Min, et al.
Publicado: (2020)

Estimated number of prevalent cases of metastatic bone disease in the US adult population
por: Li, Shuling, et al.
Publicado: (2012)

Trends in Antibiotic Treatment of Acute Otitis Media and Treatment Failure in Children, 2000–2011
por: McGrath, Leah J., et al.
Publicado: (2013)

New agents for bone metastasis
por: Hortobagyi, GN
Publicado: (2005)

Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States
por: Arellano, Jorge, et al.
Publicado: (2015)

The role of bone‐modifying agents in myeloma bone disease
por: Lu, Huifang, et al.
Publicado: (2021)

Epidemiology of benign giant cell tumor of bone in the Chinese population
por: Liede, Alexander, et al.
Publicado: (2018)

Bone-Targeted Agents and Metastasis Prevention
por: Coleman, Robert
Publicado: (2022)

Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction
por: Liede, Alexander, et al.
Publicado: (2015)

Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US
por: Altomare, Ivy, et al.
Publicado: (2016)

The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004)
por: Beebe-Dimmer, Jennifer L, et al.
Publicado: (2009)

Hospital use among patients with lung cancer complicated by bone metastases and skeletal- related events: a population-based cohort study in Denmark
por: Skov Dalgaard, Karoline, et al.
Publicado: (2015)

Combination of Bone-Modifying Agents with Immunotarget Therapy for Hepatocellular Carcinoma with Bone Metastases
por: Chen, Zhaoyu, et al.
Publicado: (2022)

Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data
por: Kim, Christopher, et al.
Publicado: (2018)

Effect of the COVID-19 pandemic on use of bone-modifying agents for metastatic breast cancer in a UK Oncology centre
por: Wang, L., et al.
Publicado: (2020)

Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis
por: Kähkönen, Tiina E., et al.
Publicado: (2021)

Insights into immuno-oncology drug development landscape with focus on bone metastasis
por: Kähkönen, Tiina E., et al.
Publicado: (2023)

Review of Bone Modifying Agents in Metastatic Breast Cancer
por: Raghu Subramanian, Charumathi, et al.
Publicado: (2021)

Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States
por: Qian, Yi, et al.
Publicado: (2017)

Controlling for Differential Regression-To-The-Mean via Propensity Scores: A Simulation Study
por: Latour, Chase D, et al.
Publicado: (2023)

Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design
por: Reams, B. Diane, et al.
Publicado: (2015)

Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents
por: Fukui, Tomoaki, et al.
Publicado: (2023)

Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer
por: Heeke, Arielle, et al.
Publicado: (2018)

Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis
por: Zhu, Mingyu, et al.
Publicado: (2019)

Bone Metastasis
por: Moore, J. V., et al.
Publicado: (1982)

Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice
por: Snell Taylor, Sara J., et al.
Publicado: (2021)

An Interesting Case of Isolated Bone Marrow Sarcoidosis
por: Iqbal, Iqra, et al.
Publicado: (2021)

Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
por: Garcia-Gomez, Antonio, et al.
Publicado: (2012)

Practical consensus recommendaton for adjuvant bone-modifying agents in breast cancer
por: Bharatuar, A., et al.
Publicado: (2018)

Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer
por: Tanaka, Hidekazu, et al.
Publicado: (2020)

The role of bone marrow adipocytes in bone metastasis
por: Morris, Emma V., et al.
Publicado: (2016)

906. Risk of Shingles among Patients Aged 45–49 versus 50–54 Years in the US, by Immune Status
por: Miles, Amanda C, et al.
Publicado: (2023)

Towards the Development of Artificial Bone Grafts: Combining Synthetic Biomineralisation with 3D Printing
por: Kurian, Mima, et al.
Publicado: (2019)

Tumor metastasis to bone
por: Virk, Mandeep S, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_lsinnf0l7nkpa919880qcrj0te